<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Mol Med</journal-id>
      <journal-title>Journal of Molecular Medicine (Berlin, Germany)</journal-title>
      <issn pub-type="ppub">0946-2716</issn>
      <issn pub-type="epub">1432-1440</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17211612</article-id>
      <article-id pub-id-type="pmc">1820751</article-id>
      <article-id pub-id-type="publisher-id">135</article-id>
      <article-id pub-id-type="doi">10.1007/s00109-006-0135-4</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>An unexpected new role of mutant Ras: perturbation of human embryonic development</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Kratz</surname>
            <given-names>Christian P.</given-names>
          </name>
          <address>
            <phone>+49-761-2704514</phone>
            <email>christian.kratz@uniklinik-freiburg.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <bio>
            <p><bold>Christian P. Kratz</bold> received his medical degree from the University of D&#xFC;sseldorf in Germany. He is presently an attending physician of Pediatrics of the Division of Pediatric Hematology/Oncology at the University of Freiburg. His research interests include genetic disorders that predispose to cancer or bone marrow failure.
<graphic position="anchor" xlink:href="109_2006_135_Figa_HTML" id="MO1"/></p>
          </bio>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Niemeyer</surname>
            <given-names>Charlotte M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zenker</surname>
            <given-names>Martin</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <bio>
            <p><bold>Martin Zenker</bold> received his medical degree from the University of Erlangen-Nuremberg in Germany. He was trained as a pediatrician and human geneticist. He is currently working as an attending physician and research group leader at the Institute of Human Genetics at the University of Erlangen-Nuremberg. His research interests include the genetic basis of human malformation syndromes.
<graphic position="anchor" xlink:href="109_2006_135_Figb_HTML" id="MO2"/></p>
          </bio>
        </contrib>
        <aff id="Aff1"><label>1</label>Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Mathildenstrasse 1, 79106 Freiburg, Germany </aff>
        <aff id="Aff2"><label>2</label>Institute of Human Genetics, University of Erlangen-Nuremberg, 91054 Erlangen, Germany </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>1</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2007</year>
      </pub-date>
      <volume>85</volume>
      <issue>3</issue>
      <fpage>227</fpage>
      <lpage>235</lpage>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>8</month>
          <year>2006</year>
        </date>
        <date date-type="rev-recd">
          <day>27</day>
          <month>10</month>
          <year>2006</year>
        </date>
        <date date-type="accepted">
          <day>30</day>
          <month>10</month>
          <year>2006</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Springer-Verlag 2007</copyright-statement>
      </permissions>
      <abstract>
        <p>The Ras signaling pathway controls important cellular responses to growth factors, and somatic mutations in <italic>RAS</italic> genes and other components of the Ras pathway, such as <italic>PTPN11</italic> (encoding the protein-tyrosine phosphatase SHP-2) and <italic>BRAF</italic>, are found in human malignancies. Ras proteins are guanosine nucleotide-binding proteins that cycle between active guanosine triphosphate (GTP)-bound and inactive guanosine diphosphate (GDP)-bound conformations. Neoplasia-associated Ras mutations frequently affect amino acids G12, G13, or Q61 and decrease the intrinsic guanosine triphosphatase (GTPase) activity by ten- to twentyfold. The GTPase activity is crucial for Ras inactivation by hydrolysis and release of a phosphate group from Ras&#xB7;GTP to produce Ras&#xB7;GDP. We and others have recently discovered germline mutations in the <italic>KRAS</italic> gene in individuals diagnosed with Noonan and cardio&#x2013;facio&#x2013;cutaneous (CFC) syndrome, two clinically overlapping disorders characterized by short stature, distinct facial anomalies, heart defects, and other abnormalities. Noonan syndrome-associated mutations V14I and T58I K-Ras activate Ras but have milder biochemical effects than somatic mutations encountered in cancers, offering an explanation why these K-Ras lesions are tolerated during embryonic development. Together with recent findings of <italic>BRAF</italic>, <italic>MEK1</italic>, and <italic>MEK2</italic> mutations in CFC syndrome and <italic>HRAS</italic> mutations in Costello syndrome, another clinically related disorder, it has now become clear that Noonan-like features (short stature, relative macrocephaly, facial anomalies, learning difficulties) that are found in these three related disorders are a result of constitutive activation of the Ras&#x2013;Raf&#x2013;extracellular signal-regulated and mitogen-activated protein kinase pathway.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Noonan syndrome</kwd>
        <kwd>Cardio&#x2013;facio&#x2013;cutaneous syndrome</kwd>
        <kwd>Costello syndrome</kwd>
        <kwd>Neurofibromatosis type 1</kwd>
        <kwd>Ras signaling</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2007</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title><italic>RAS</italic> genes</title>
      <p>The three human <italic>RAS</italic> genes, <italic>KRAS</italic> (isoforms A and B), <italic>NRAS</italic>, and <italic>HRAS</italic> (isoforms 1 and 2), encode small, highly conserved guanosine triphosphatases (GTPases) that relay growth signals to a number of effector proteins to control fundamental cellular pathways (reviewed in [<xref ref-type="bibr" rid="CR1">1</xref>]). Ras proteins act as molecular switches by cycling between an active guanosine triphosphate (GTP)-bound and an inactive guanosine diphosphate (GDP)-bound state. Stimulated growth factor receptors recruit a number of adaptor proteins that activate guanosine nucleotide exchange factors (GEFs) to remove guanine nucleotides from Ras. Ras is then activated by binding to GTP, which is present at a tenfold higher concentration than GDP. In the GTP-bound state, the two switch regions of Ras (switch I and II) change their conformation. This conformational switch allows Ras to bind and activate Ras effector proteins such as Raf-1. The &#x201C;on&#x201D; position is turned &#x201C;off&#x201D; by an intrinsic GTPase activity, which hydrolyses and releases a phosphate group from Ras&#xB7;GTP to produce Ras&#xB7;GDP. The conformational transition of the switch I and II regions that is associated with this reaction disrupts the interaction between Ras and its effectors. The intrinsic GTPase activity of Ras is slow and accelerated about 10<sup>5</sup>-fold by GTPase activating proteins (GAPs), such as neurofibromin or p120 GAP. These GAPs mediate Ras&#xB7;GTP hydrolysis by inserting an arginine residue (arginine finger) into the phosphate-binding pocket of Ras (reviewed in [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]; Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Ras cycles between an active GTP-bound and an inactive GDP-bound conformation. In the active state, the two switch regions, switch I and II, change their conformation allowing Ras to activate effector proteins. The intrinsic GTPase hydrolyzes a phosphate group to produce Ras&#xB7;GDP. This reaction is accelerated by GTPase activating proteins (<italic>GAPs</italic>). A similar version of this figure has been previously published [<xref ref-type="bibr" rid="CR61">61</xref>], republication with permission</p></caption><graphic position="anchor" xlink:href="109_2006_135_Fig1_HTML" id="MO3"/></fig></p>
      <p>For several decades, it has been well recognized that <italic>RAS</italic> genes are frequently mutated in human cancers (reviewed in [<xref ref-type="bibr" rid="CR4">4</xref>]). These mutations predominantly lead to amino acid substitutions at residues G12, G13, or Q61 and lock Ras in the active GTP-bound state by diminishing the intrinsic Ras GTPase activity and/or by causing resistance to GAPs. These mutations were long believed to occur only as somatic events, and in a mouse model system, widespread expression of endogenous K-Ras<sup>G12D</sup> leads to embryonic death [<xref ref-type="bibr" rid="CR5">5</xref>]. The highest incidence of <italic>RAS</italic> mutations are found in adenocarcinomas of the pancreas (90%), the colon (50%), and the lung (30%), in thyroid tumors (50%), and in myeloid leukemia (30%) [<xref ref-type="bibr" rid="CR4">4</xref>].</p>
    </sec>
    <sec id="Sec2">
      <title>Noonan syndrome and related disorders</title>
      <p>Noonan syndrome (NS; MIM 163950) is an autosomal dominant disorder characterized by short stature, distinct facial anomalies (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>), a typical spectrum of congenital heart defects, including pulmonic stenosis, hypertrophic cardiomyopathy, and septal defects, and developmental delays (reviewed [<xref ref-type="bibr" rid="CR6">6</xref>]). The disorder occurs in approximately 1 out of 2,000 individuals and shares many features with the much less common disorders of Costello syndrome (CS), cardio&#x2013;facio&#x2013;cutaneous (CFC) syndrome, and lentigines, electrocardiographic conduction defects, ocular hypertelorism, pulmonary stenosis, abnormalities of the genitals; retarded growth resulting in short stature, and deafness (LEOPARD) syndrome (LS) [<xref ref-type="bibr" rid="CR6">6</xref>]. Patients with these disorders have in common Noonan-like facial features, a similar spectrum of cardiac anomalies, delayed growth, and&#x2014;to a variable degree&#x2014;developmental retardation, which is stronger in patients with CS or CFC. In addition, each of these disorders is characterized by unique phenotypic patterns: (1) CS patients have nasal papillomata, loose skin, and a strong predisposition to tumors (mainly rhabdomyosarcoma) [<xref ref-type="bibr" rid="CR7">7</xref>]; (2) CFC patients have ectodermal abnormalities with sparse curly hair, sparse, or absent eyelashes [<xref ref-type="bibr" rid="CR8">8</xref>]; and (3) LS patients have multiple lentigines typically emerging during adolescence [<xref ref-type="bibr" rid="CR6">6</xref>]. NS and LS may be familial with an autosomal dominant inheritance pattern (except for rare instances of NS where rare recessive inheritance has been suspected [<xref ref-type="bibr" rid="CR9">9</xref>]), but most cases of these disorders and virtually all of the more severe conditions, CFC and CS, occur sporadically, suggesting dominant new mutations. Until recently, the genetic basis for these disorders was unknown. It was not clear whether they represented genetically distinct entities or if they were different (allelic) variants of a common disorder. By linkage analysis in families with NS, the disorder was mapped to chromosome 12q24 [<xref ref-type="bibr" rid="CR10">10</xref>], and subsequently, it has been shown that approximately 50% of patients with NS carry germline mutations in <italic>PTPN11</italic> [<xref ref-type="bibr" rid="CR11">11</xref>]. The <italic>PTPN11</italic> gene encodes for tyrosine-protein phosphatase (SHP-2), a phosphatase that relays growth signals from activated growth factor receptors to other signaling molecules, including Ras (reviewed in [<xref ref-type="bibr" rid="CR12">12</xref>]). Most <italic>PTPN11</italic> mutations are predicted to disrupt the auto-inhibition of the catalytic phosphatase domain (PTPase) by the N-terminal src-homology 2 (N-SH2) domain thereby promoting the active conformation of the protein [<xref ref-type="bibr" rid="CR12">12</xref>]. <italic>PTPN11</italic> mutations were not found in patients with CS or CFC syndromes (reviewed in [<xref ref-type="bibr" rid="CR6">6</xref>]). However, specific mutations in the same gene were uncovered in patients with LS [<xref ref-type="bibr" rid="CR13">13</xref>]. Surprisingly, in contrast to NS, LS mutants are catalytically defective and may act as dominant negative mutations [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Molecular modeling and biochemical studies suggest that LS mutations disrupt the SHP-2 catalytic domain to result in open, inactive forms of SHP-2. Thus, the pathogenesis of LS and NS is distinct. It is unknown why the clinical phenotypes of LS and NS are similar although the underlying mutations have opposite biochemical effects. There are several possible explanations for this paradox. These are discussed in detail by Kontaridis et al. [<xref ref-type="bibr" rid="CR14">14</xref>]: (1) The NS and LS phenotypes potentially result from differential effects of mutant SHP-2 on different receptor tyrosine kinase pathways at distinct developmental times. For example, recent work by others suggests that the main effect of NS mutants is to enhance epithelial&#x2013;mesenchymal transformation/mesenchymal cell proliferation by increasing ErbB2/3 (and/or ErbB3/4) signaling. By contrast, LS mutants antagonize HB-EGF/ErbB1 signaling at later times [<xref ref-type="bibr" rid="CR14">14</xref>]; (2) Other phenotypes common to NS and LS such as facial abnormalities and short stature might involve defective migration and/or differentiation, which might result from increased or decreased signaling involving the same pathway; (3) Yet, undetermined or poorly understood functions of SHP-2 might underlie pathogenesis of one or both of these disorders [<xref ref-type="bibr" rid="CR14">14</xref>].
<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p><bold>a</bold> Craniofacial phenotype of young children with NS, CFC, and CS aged between 10 and 18&#xA0;months. Their genotypes are <italic>PTPN11</italic> G503R, <italic>BRAF</italic> K499E, and <italic>HRAS</italic> G13C, respectively. Note the similarities of facial features, including hypertelorism, broad forehead, and low-set ears. Coarse facial features are particularly typical of CS. <bold>b</bold> The same disorders in older children and adolescents with the mutations <italic>PTPN11</italic> N308D, <italic>MEK2</italic> F57I, and <italic>HRAS</italic> G12S, respectively. Facial features become more distinct with age, although the similarities of the three syndromes are still evident. Courtesy of Prof. Rainer K&#xF6;nig, Frankfurt (images of CFC patients) and Prof. Kerstin Kutsche, Hamburg (images of CS patients)</p></caption><graphic position="anchor" xlink:href="109_2006_135_Fig2_HTML" id="MO4"/></fig></p>
    </sec>
    <sec id="Sec3">
      <title>The Noonan gene <italic>PTPN11</italic> also acts as oncogene</title>
      <p>One of the myeloid malignancies that has been found to be particularly related to perturbed Ras signaling is juvenile myelomonocytic leukemia (JMML), a myeloproliferative disorder (MPD) of early childhood [<xref ref-type="bibr" rid="CR16">16</xref>], in which mutations occur in <italic>NRAS</italic> or <italic>KRAS</italic> (&#x223C;25%) or in <italic>NF1</italic> (clinical diagnosis of neurofibromatosis type 1 in &#x223C;11%) [<xref ref-type="bibr" rid="CR17">17</xref>&#x2013;<xref ref-type="bibr" rid="CR19">19</xref>]. In a murine model, somatic activation of K-Ras in hematopoietic cells initiates a rapidly fatal MPD modeling JMML [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Despite a low annual incidence estimated at 1&#x2013;2 per million, JMML has attracted many clinical and basic researchers because of the severe and often lethal clinical course and the association with NS [<xref ref-type="bibr" rid="CR22">22</xref>] and neurofibromatosis type 1 (NF1; MIM 162200; reviewed in [<xref ref-type="bibr" rid="CR19">19</xref>]). Shortly after the discovery of <italic>PTPN11</italic> mutations in individuals with NS, specific germline <italic>PTPN11</italic> alterations were identified in young children with NS who developed a JMML-like disorder within the first few weeks of birth (NS/JMML) [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>], and somatic <italic>PTPN11</italic> mutations were subsequently uncovered in JMML cells from 35% of children with non-syndromic JMML [<xref ref-type="bibr" rid="CR23">23</xref>&#x2013;<xref ref-type="bibr" rid="CR25">25</xref>]. Somatic <italic>PTPN11</italic> mutations also occur in B-cell precursor acute lymphoblastic leukemia [<xref ref-type="bibr" rid="CR26">26</xref>] and rarely other malignancies [<xref ref-type="bibr" rid="CR27">27</xref>]. Somatic mutations observed in patients with JMML differ from those mutations found in patients with NS/JMML and from those detected in patients with NS alone. In sporadic JMML, the most common mutation predicts an E76K substitution. This mutation has never been found in patients with NS (N308D most common) or NS/JMML (T73I most common) [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. In elegant functional experiments, several groups have shown that somatic <italic>PTPN11</italic> mutations associated with sporadic JMML exhibit stronger biochemical and biological effects than germline <italic>PTPN11</italic> mutations, leading to the concept that only milder SHP-2 activation may be tolerated during embryonic development [<xref ref-type="bibr" rid="CR28">28</xref>&#x2013;<xref ref-type="bibr" rid="CR30">30</xref>]. The situation is too complex however to be explained by a simple model of strong activating somatic vs less activating germline mutations alone. Enzymatic, structural, and mathematical modeling analyses show that these mutants can affect basal activation, SH2 domain-phosphopeptide affinity, and/or substrate specificity to varying degrees, and there is no absolute correlation between the mutants&#x2019; extents of basal activation and the diseases they induce [<xref ref-type="bibr" rid="CR31">31</xref>]. A murine knock-in <italic>Ptpn11</italic><sup>D61G/+</sup> model of NS has been constructed, revealing that endocardial cushions of these mice have increased activation of extracellular signal-regulated kinase [<xref ref-type="bibr" rid="CR32">32</xref>]. This finding suggests that the phenotype exhibited by <italic>PTPN11</italic> mutations is mediated through hyperactive Ras signaling.</p>
    </sec>
    <sec id="Sec4">
      <title>Neurofibromatosis type 1</title>
      <p>JMML is also associated with NF1 (MIM 162200), an autosomal dominant disorder that occurs in 1 of 4,000 births and is characterized by pigmentary anomalies (multiple caf&#xE9;-au-lait spots) and a predisposition to benign and malignant tumors of mainly neurogenic origin. The disorder is caused by mutations in the <italic>NF1</italic> tumor suppressor gene, which encodes the RasGAP neurofibromin. The incidence of JMML is increased approximately 200-fold in children with NF1 (reviewed in [<xref ref-type="bibr" rid="CR33">33</xref>]). Loss of the normal <italic>NF1</italic> allele (LOH, loss of heterozygosity) is common in JMML cells from children with NF1 [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], and this results in severely deregulated Ras signaling and causes aberrant growth of hematopoietic progenitor colonies in vitro [<xref ref-type="bibr" rid="CR36">36</xref>]. In addition, adoptive transfer of homozygous <italic>Nf1</italic> mutant fetal liver cells or somatic inactivation of a conditional mutant <italic>Nf1</italic> allele in hematopoietic cells induces a JMML-like MPD in mice [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Remarkably, many NF1 patients have mild features reminiscent of NS [<xref ref-type="bibr" rid="CR39">39</xref>], and some may even develop a mixed phenotype, which has prompted the definition of neurofibromatosis&#x2013;NS (NFNS; MIM 601321) as a separate entity. Most patients who are diagnosed with this condition harbor <italic>NF1</italic> mutations without an obvious genotype&#x2013;phenotype correlation [<xref ref-type="bibr" rid="CR40">40</xref>].</p>
    </sec>
    <sec id="Sec5">
      <title>Additional genes mutated in Noonan syndrome</title>
      <p>To date, the identification of additional NS genes was hampered by the fact that the vast majority of <italic>PTPN11</italic> mutation-negative NS-patients represent sporadic cases [<xref ref-type="bibr" rid="CR41">41</xref>], rendering genetic linkage studies impossible. However, recent findings by our group and others identified germline mutations in components of the Ras signaling pathway in individuals with NS or related syndromes [<xref ref-type="bibr" rid="CR42">42</xref>&#x2013;<xref ref-type="bibr" rid="CR46">46</xref>]. We systematically screened patients with NS and CFC for <italic>RAS</italic> mutations after having discovered a novel de novo germline <italic>KRAS</italic> mutation in a patient with NS/JMML [<xref ref-type="bibr" rid="CR42">42</xref>]. The mutation c.173C&gt;T (p.T58I) detected in the index patient affects a highly conserved amino acid residue of K-Ras flanking the switch II region (amino acids 59&#x2013;67) of the protein. De novo <italic>KRAS</italic> mutations were identified in 4 of 174 sporadic cases with NS previously excluded for <italic>PTPN11</italic> mutations. All germline <italic>KRAS</italic> mutations were novel and not known to occur in human cancer. NS-associated <italic>KRAS</italic> alleles included recurrent mutations, V14I and D153V. The latter was confirmed in patients with more severe phenotypes [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Analogous to the dual role of <italic>PTPN11</italic> as both oncogene and developmental gene, this discovery led to the hypothesis that activating <italic>KRAS</italic> mutations do not only act as oncogenes; aberrant K-Ras can also cause developmental disorders when mutations&#x2014;probably conferring relatively mild effects&#x2014;emerge in the germline. To prove our hypothesis, we studied the functional properties of V14I and T58I K-Ras [<xref ref-type="bibr" rid="CR42">42</xref>] and found both NS-associated mutants V14I and T58I to have intermediate biochemical (e.g., ability to hydrolyze Ras&#xB7;GTP) and biological properties (e.g., growth behavior in response to growth factors after retroviral transfection) when compared with wild-type K-Ras and the oncogenic mutant K-Ras G12D [<xref ref-type="bibr" rid="CR42">42</xref>].</p>
      <p>The two aforementioned mutations, V14I and T58I, are located adjacent to amino acid residues that are typically altered in cancer (G12, G13, or Q61). They locate to regions of Ras that are known to be involved in GTP binding. By contrast, in a subset of NS patients, <italic>KRAS</italic> mutations lead to substitutions in protein regions not obviously involved in GTP binding (e.g., D153V K-Ras), indicating the existence of previously unappreciated mechanisms of Ras activation. Carta et al. [<xref ref-type="bibr" rid="CR46">46</xref>] performed a structural analysis on the two K-Ras mutants, V152G and D153V, that these investigators identified in two patients with severe NS. Their computer-based analysis indicated that both mutations disturb the conformation of the guanine ring-binding pocket favoring the active GTP-bound conformation by increasing the guanine nucleotide dissociation rate. Additionally, these residues are predicted to be important for binding the RasGEF son of sevenless (SOS) [<xref ref-type="bibr" rid="CR47">47</xref>]. In the meantime, we have detected a number of additional <italic>KRAS</italic> mutations associated with NS (Q22R, P34L, P34Q, I36M), all of which affect highly conserved amino acid residues and are assumed to confer (mild) gain of function [<xref ref-type="bibr" rid="CR48">48</xref>]. In this study on additional 236 <italic>PTPN11</italic>-negative NS patients, we detected <italic>KRAS</italic> mutations in seven individuals [<xref ref-type="bibr" rid="CR48">48</xref>], thus confirming that <italic>KRAS</italic> accounts for less than 5% of NS cases.</p>
    </sec>
    <sec id="Sec6">
      <title>Genes mutated in cardio&#x2013;facio&#x2013;cutaneous syndrome</title>
      <p>In our initial study, we also discovered a novel K-Ras mutation, K-Ras P34R, in 1 of 12 patients with CFC syndrome [<xref ref-type="bibr" rid="CR42">42</xref>]. This mutation is now known to be located in another mutational hotspot associated with NS [<xref ref-type="bibr" rid="CR48">48</xref>]. A P34R H-Ras lesion has been previously characterized by Stone et al. [<xref ref-type="bibr" rid="CR49">49</xref>]. These investigators employed a mutagenesis strategy during which they found that H-Ras P34R binds to GTP in vivo. In vitro, H-Ras P34R is not stimulated by GAPs [<xref ref-type="bibr" rid="CR49">49</xref>]. Considering the highly conserved G-domain structure of Ras proteins, the P34R K-Ras mutation presumably has very similar (if not identical) biochemical properties. The presence of K-Ras mutations in CFC syndrome was confirmed by Niihori et al. [<xref ref-type="bibr" rid="CR44">44</xref>] who analyzed DNA specimens from 43 individuals with CFC syndrome and found two <italic>KRAS</italic> germline mutations (G60R and D153V) in three patients. Notably, the D153V K-Ras mutation also has been described in patients with NS [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. In a more recent study, we identified additional K-Ras mutations in individuals with CFC or NS/CFC including Q22E and F156I. The observations that mutations, such as K-Ras F156I, may be associated with an overlap of NS and CFC suggest that there is not a very strict genotype&#x2013;phenotype correlation [<xref ref-type="bibr" rid="CR48">48</xref>]. Simultaneous to the finding of mutated K-Ras in CFC, Niihori et al. identified <italic>BRAF</italic> germline mutations in 16 of 43 CFC patients [<xref ref-type="bibr" rid="CR36">36</xref>]. At the same time, another group found <italic>BRAF</italic> germline mutations in 18 of 23 CFC patients and <italic>MEK1</italic> or <italic>MEK2</italic> germline mutations in 3 of the remaining 5 CFC patients studied [<xref ref-type="bibr" rid="CR45">45</xref>]. Like <italic>PTPN11</italic> and <italic>RAS</italic>, <italic>BRAF</italic> is a known oncogene, and somatic mutations are frequently found in cancer [<xref ref-type="bibr" rid="CR50">50</xref>].</p>
    </sec>
    <sec id="Sec7">
      <title>The molecular basis of Costello syndrome</title>
      <p>Shortly before germline <italic>KRAS</italic> mutations were described in patients with NS and CFC, <italic>HRAS</italic> germline mutations were reported to cause CS [<xref ref-type="bibr" rid="CR43">43</xref>]. Later, other investigators also detected these mutations in the majority (&#x223C;90%) of CS patients studied [<xref ref-type="bibr" rid="CR51">51</xref>&#x2013;<xref ref-type="bibr" rid="CR53">53</xref>]. Surprisingly, these germline lesions affect the same amino acid residues of H-Ras that are also mutated in cancer. The observation that activating oncogenic H-Ras mutations affecting codons G12 or G13 are tolerated in the germline, whereas oncogenic K-Ras mutations affecting these residues are not, underscores the notion that although H-Ras and K-Ras are structurally highly similar, they play different roles during embryonic development. Knockout studies have shown that only K-Ras is essential for embryonic development, whereas N-Ras and H-Ras are not [<xref ref-type="bibr" rid="CR54">54</xref>]. Different phenotypes exhibited by mutations in various Ras isoforms may be due to heterogenous expression patterns of these proteins. Additionally, various Ras isoforms undergo different processing, e.g., de/repalmitoylation kinetics that regulate subcellular localization and activity of Ras isoforms [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. Although the vast majority of patients with CS harbor <italic>HRAS</italic> mutations, very recent studies have indicated that a CS phenotype may occasionally be associated with specific mutations of <italic>BRAF</italic> [<xref ref-type="bibr" rid="CR57">57</xref>] or <italic>KRAS</italic> [<xref ref-type="bibr" rid="CR48">48</xref>]. It remains to be determined if these patients also have the increased risk of neoplasia, which is typical of CS. Therefore, we doubt it is useful to classify these patients with mutations in Ras pathway genes other that <italic>HRAS</italic> as CS.</p>
    </sec>
    <sec id="Sec8">
      <title>Neuro&#x2013;cardio&#x2013;facial&#x2013;cutaneous syndrome</title>
      <p>The molecular explanation of how different germline K-Ras or H-Ras mutations cause a wide spectrum of different phenotypes is still largely unknown. Activating germline K-Ras mutations may be associated with the broadest spectrum of clinical manifestations [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. However, these syndromes are not just a less or more severe expression of essentially the same disorder. Therefore, it is conceivable that the different <italic>RAS</italic> mutations associated with divergent phenotypes do not only vary quantitatively in their degree of constitutive activation. Unique lesions may also have different qualitative effects on downstream signaling pathways. Additionally, modifier loci may play a role. Recently, the term &#x2018;neuro&#x2013;cardio&#x2013;facial&#x2013;cutaneous&#x2019; (NCFC) syndrome [<xref ref-type="bibr" rid="CR58">58</xref>] was coined to illustrate that clinically overlapping disorders of the NS spectrum, including NF1, NS, CS, LS, and CFC syndrome, are caused by mutations in components of the Ras signaling pathway (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). We speculate that the phenotypic variability between these disorder results from (1) different expression patterns of affected genes/isoforms and (2) variable mechanisms by which certain mutants interact with downstream effectors or regulatory proteins; these mutants therefore perturb Ras signaling in varying degrees. Further research is required to determine the basis of genotype&#x2013;phenotype correlations in NS and related disorders.
<fig id="Fig3"><label>Fig.&#xA0;3</label><caption><p>The Ras signaling pathway relays growth signals from activated growth factor receptors to the nucleus. Somatic mutations in several molecules of the pathway have been implicated in cancer. It is now recognized that germline mutations of identical molecules may cause disorders of the Noonan spectrum. A similar version of this figure has been previously published [<xref ref-type="bibr" rid="CR61">61</xref>], republication with permission</p></caption><graphic position="anchor" xlink:href="109_2006_135_Fig3_HTML" id="MO5"/></fig></p>
    </sec>
    <sec id="Sec9">
      <title>Neurofibromatosis Noonan syndrome and NS-like features in neurofibromatosis</title>
      <p>The rapidly increasing knowledge of the Ras signaling pathway and its relation to developmental disorders of the NS spectrum suggests that Noonan-like features are the clinical correlate of any genetic abnormality occurring in the germline and leading to a generalized mild deregulation of the Ras signaling cascade(s) during embryonic development. The new insights gained by recent research in this field may explain the phenotypic similarities between individuals with NF1 and NS. In addition to the well-known symptoms defining NF1, namely multiple caf&#xE9;-au-lait spots and cutaneous neurofibromas, patients with NF1 are known to exhibit NS features, including relative short stature, relative macrocephaly, mild facial anomalies, thorax deformities, and learning difficulties. NFNS probably just represents the extreme end of a highly variable expression of these features [<xref ref-type="bibr" rid="CR59">59</xref>]. Although the association of NF1 and NS was described in one family with independently segregating mutations in <italic>NF1</italic> and <italic>PTPN11</italic> [<xref ref-type="bibr" rid="CR60">60</xref>], this double chance event is not the causative mechanism in many other patients with NF1 and NS-like features. The majority of patients with the NFNS phenotype have been found to harbor <italic>NF1</italic> mutations, some of which also occur in patients with &#x201C;pure&#x201D; NF1 [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. We propose that the NS-like features that are often present in patients with NF1 are potentially due to <italic>NF1</italic> haploinsufficiency leading to decreased inactivation of Ras&#xB7;GTP. This might cause mild constitutional deregulation of Ras signaling, which may occasionally reach a level that leads to a NF1-NS phenotype. Frequently, patients with NF1 have mild features of NS. These may be explained by a mild activation of Ras, which is due to loss-of-function of one <italic>NF1</italic> allele. Unknown genetic modifiers may play a role. Malignant cells arising in patients with NF1 somatically loose the wild-type <italic>NF1</italic> allele. This second somatic hit ablates the GAP function of neurofibromin resulting in strongly enhanced Ras signaling (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>).
<fig id="Fig4"><label>Fig.&#xA0;4</label><caption><p>Model illustrating the molecular basis of how Ras signaling may be increased in patients with neurofibromatosis type 1 leading to Noonan-like feature in these patients. Although only one <italic>NF1</italic> allele is inactive in the germline, tumors of patients with neurofibromatosis type 1 somatically lose the second, wild-type <italic>NF1</italic> allele</p></caption><graphic position="anchor" xlink:href="109_2006_135_Fig4_HTML" id="MO6"/></fig></p>
    </sec>
    <sec id="Sec10">
      <title>Work in progress</title>
      <p>Although the vast majority of cases with CFC and CS are explained by mutations in <italic>KRAS</italic>, <italic>BRAF</italic>, <italic>MEK1</italic>, <italic>MEK2</italic>, and <italic>HRAS</italic>, the underlying genetic defect in 50% of NS and 10&#x2013;30% of CFC cases remains unknown. Based on the assumption that the NS phenotype results from hyperactive Ras signaling, we and others are currently screening DNA specimens from patients for mutations in genes encoding for other components, including negative regulators, of the Ras pathway. Analogous to <italic>PTPN11</italic> and <italic>KRAS</italic>, currently unknown genes of the Ras pathway mutated in NS are presumably playing double roles in both development and oncogenesis. Mutations in <italic>BRAF</italic> and <italic>MEK1</italic>/<italic>2</italic> have been excluded as major NS genes (M.Z., unpublished data).</p>
      <p>It will be of interest to study how the different expression patterns of various <italic>RAS</italic> genes and isoforms influence clinical phenotypes when these genes/isoforms are mutated in the germline. It will be crucial to elucidate the structural mechanisms to understand how these new lesions perturb signaling on a molecular level. Characterization of the biological consequences of these mutations will be largely improved by the construction of murine knock-in models.</p>
    </sec>
    <sec id="Sec11">
      <title>Note added in proof</title>
      <p>After this paper was accepted we uncovered mutations in <italic>SOS1</italic> encoding for the homonymous RasGEF in patients with NS. Meanwhile, however, two other groups have published elegant reports on activating <italic>SOS1</italic> mutations in approximately 10% of cases with NS: Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin Y, Tamburino AM, Neel BG, Kucherlapati RS. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet. 2006 Dec 3; [Epub ahead of print] Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry CJ, Siguero JP, Digilio MC, Zampino G, Dallapiccola B, Bar-Sagi D, Gelb BD. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet. 2006 Dec 3; [Epub ahead of print]&#x201D;.</p>
    </sec>
  </body>
  <back>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Repasky</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Chenette</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Der</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis</article-title>
          <source>Trends Cell Biol</source>
          <year>2004</year>
          <volume>14</volume>
          <fpage>639</fpage>
          <lpage>647</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tcb.2004.09.014</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Repasky GA, Chenette EJ, Der CJ (2004) Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol 14:639&#x2013;647 <pub-id pub-id-type="pmid">15519853</pub-id></citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vetter</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>Wittinghofer</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>The guanine nucleotide-binding switch in three dimensions</article-title>
          <source>Science</source>
          <year>2001</year>
          <volume>294</volume>
          <fpage>1299</fpage>
          <lpage>1304</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1062023</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Vetter IR, Wittinghofer A (2001) The guanine nucleotide-binding switch in three dimensions. Science 294:1299&#x2013;1304 <pub-id pub-id-type="pmid">11701921</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Donovan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Bollag</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>GTPase activating poteins: critical regulators of intracellular signaling</article-title>
          <source>BBA Rev Cancer</source>
          <year>2002</year>
          <volume>1602</volume>
          <fpage>23</fpage>
          <lpage>45</lpage>
        </citation>
        <citation citation-type="display-unstructured">Donovan S, Shannon KM, Bollag G (2002) GTPase activating poteins: critical regulators of intracellular signaling. BBA Rev Cancer 1602:23&#x2013;45 </citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bos</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Ras oncogenes in human cancer: a review</article-title>
          <source>Cancer Res</source>
          <year>1989</year>
          <volume>49</volume>
          <fpage>4682</fpage>
          <lpage>4689</lpage>
        </citation>
        <citation citation-type="display-unstructured">Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49:4682&#x2013;4689 <pub-id pub-id-type="pmid">2547513</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tuveson</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Willis</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Silver</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mercer</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Grochow</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hock</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Crowley</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hingorani</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Zaks</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jacobetz</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bronson</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Orkin</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>DePinho</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Jacks</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects</article-title>
          <source>Cancer Cell</source>
          <year>2004</year>
          <volume>5</volume>
          <fpage>375</fpage>
          <lpage>387</lpage>
          <pub-id pub-id-type="doi">10.1016/S1535-6108(04)00085-6</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, King C, Jacobetz MA, Wang L, Bronson RT, Orkin SH, DePinho RA, Jacks T (2004) Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5:375&#x2013;387 <pub-id pub-id-type="pmid">15093544</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tartaglia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gelb</surname>
              <given-names>BD</given-names>
            </name>
          </person-group>
          <article-title>Noonan syndrome and related disorders: genetics and pathogenesis</article-title>
          <source>Annu Rev Genomics Hum Genet</source>
          <year>2005</year>
          <volume>6</volume>
          <fpage>45</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.genom.6.080604.162305</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tartaglia M, Gelb BD (2005) Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet 6:45&#x2013;68 <pub-id pub-id-type="pmid">16124853</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hennekam</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Costello syndrome: an overview</article-title>
          <source>Am J Med Genet C Semin Med Genet</source>
          <year>2003</year>
          <volume>117</volume>
          <fpage>42</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="doi">10.1002/ajmg.c.10019</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hennekam RC (2003) Costello syndrome: an overview. Am J Med Genet C Semin Med Genet 117:42&#x2013;48 <pub-id pub-id-type="pmid">12561057</pub-id></citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kavamura</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Peres</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Alchorne</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Brunoni</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>CFC index for the diagnosis of cardiofaciocutaneous syndrome</article-title>
          <source>Am J Med Genet</source>
          <year>2002</year>
          <volume>112</volume>
          <fpage>12</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="doi">10.1002/ajmg.10681</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kavamura MI, Peres CA, Alchorne MM, Brunoni D (2002) CFC index for the diagnosis of cardiofaciocutaneous syndrome. Am J Med Genet 112:12&#x2013;16 <pub-id pub-id-type="pmid">12239713</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burgt</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Brunner</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Genetic heterogeneity in Noonan syndrome: evidence for an autosomal recessive form</article-title>
          <source>Am J Med Genet</source>
          <year>2000</year>
          <volume>94</volume>
          <fpage>46</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="doi">10.1002/1096-8628(20000904)94:1&lt;46::AID-AJMG10&gt;3.0.CO;2-I</pub-id>
        </citation>
        <citation citation-type="display-unstructured">van der Burgt I, Brunner H (2000) Genetic heterogeneity in Noonan syndrome: evidence for an autosomal recessive form. Am J Med Genet 94:46&#x2013;51 <pub-id pub-id-type="pmid">10982482</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jamieson</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Burgt</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Brady</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Reen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Elsawi</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Hol</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Jeffery</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Patton</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Mariman</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Mapping a gene for Noonan syndrome to the long arm of chromosome 12</article-title>
          <source>Nat Genet</source>
          <year>1994</year>
          <volume>8</volume>
          <fpage>357</fpage>
          <lpage>359</lpage>
          <pub-id pub-id-type="doi">10.1038/ng1294-357</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Jamieson CR, van der Burgt I, Brady AF, van Reen M, Elsawi MM, Hol F, Jeffery S, Patton MA, Mariman E (1994) Mapping a gene for Noonan syndrome to the long arm of chromosome 12. Nat Genet 8:357&#x2013;359 <pub-id pub-id-type="pmid">7894486</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tartaglia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mehler</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Goldberg</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zampino</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Brunner</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Kremer</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Burgt</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Crosby</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Ion</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jeffery</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kalidas</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Patton</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Kucherlapati</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Gelb</surname>
              <given-names>BD</given-names>
            </name>
          </person-group>
          <article-title>Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome</article-title>
          <source>Nat Genet</source>
          <year>2001</year>
          <volume>29</volume>
          <fpage>465</fpage>
          <lpage>468</lpage>
          <pub-id pub-id-type="doi">10.1038/ng772</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD (2001) Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29:465&#x2013;468 <pub-id pub-id-type="pmid">11704759</pub-id></citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neel</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Gu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Pao</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>The &#x2018;Shp&#x2019;ing news: SH2 domain-containing tyrosine phosphatases in cell signaling</article-title>
          <source>Trends Biochem Sci</source>
          <year>2003</year>
          <volume>28</volume>
          <fpage>284</fpage>
          <lpage>293</lpage>
          <pub-id pub-id-type="doi">10.1016/S0968-0004(03)00091-4</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Neel BG, Gu H, Pao L (2003) The &#x2018;Shp&#x2019;ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28:284&#x2013;293 <pub-id pub-id-type="pmid">12826400</pub-id></citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Digilio</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Conti</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sarkozy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mingarelli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dottorini</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Marino</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Pizzuti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dallapiccola</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene</article-title>
          <source>Am J Hum Genet</source>
          <year>2002</year>
          <volume>71</volume>
          <fpage>389</fpage>
          <lpage>394</lpage>
          <pub-id pub-id-type="doi">10.1086/341528</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T, Marino B, Pizzuti A, Dallapiccola B (2002) Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 71:389&#x2013;394 <pub-id pub-id-type="pmid">12058348</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kontaridis</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Swanson</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Barford</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Neel</surname>
              <given-names>BG</given-names>
            </name>
          </person-group>
          <article-title>PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects</article-title>
          <source>J Biol Chem</source>
          <year>2006</year>
          <volume>281</volume>
          <fpage>6785</fpage>
          <lpage>6792</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M513068200</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG (2006) PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem 281:6785&#x2013;6792 <pub-id pub-id-type="pmid">16377799</pub-id></citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tartaglia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Martinelli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Stella</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bocchinfuso</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Flex</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Cordeddu</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Zampino</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Burgt</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Palleschi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Petrucci</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Sorcini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schoch</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Foa</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Emanuel</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Gelb</surname>
              <given-names>BD</given-names>
            </name>
          </person-group>
          <article-title>Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease</article-title>
          <source>Am J Hum Genet</source>
          <year>2006</year>
          <volume>78</volume>
          <fpage>279</fpage>
          <lpage>290</lpage>
          <pub-id pub-id-type="doi">10.1086/499925</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, Cordeddu V, Zampino G, Burgt I, Palleschi A, Petrucci TC, Sorcini M, Schoch C, Foa R, Emanuel PD, Gelb BD (2006) Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 78:279&#x2013;290 <pub-id pub-id-type="pmid">16358218</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niemeyer</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Arico</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Basso</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Biondi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cantu Rajnoldi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Creutzig</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Haas</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Harbott</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hasle</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kerndrup</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Locatelli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Stollmann-Gibbels</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Veer-Korthof</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Wering</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Zimmermann</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)</article-title>
          <source>Blood</source>
          <year>1997</year>
          <volume>89</volume>
          <fpage>3534</fpage>
          <lpage>3543</lpage>
        </citation>
        <citation citation-type="display-unstructured">Niemeyer CM, Arico M, Basso G, Biondi A, Cantu Rajnoldi A, Creutzig U, Haas O, Harbott J, Hasle H, Kerndrup G, Locatelli F, Mann G, Stollmann-Gibbels B, van&#x2019;t Veer-Korthof ET, van Wering E, Zimmermann M (1997) Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood 89:3534&#x2013;3543 <pub-id pub-id-type="pmid">9160658</pub-id></citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flotho</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Valcamonica</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mach-Pascual</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schmahl</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Corral</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ritterbach</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hasle</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Arico</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Biondi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Niemeyer</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML)</article-title>
          <source>Leukemia</source>
          <year>1999</year>
          <volume>13</volume>
          <fpage>32</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="doi">10.1038/sj/leu/2401240</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Flotho C, Valcamonica S, Mach-Pascual S, Schmahl G, Corral L, Ritterbach J, Hasle H, Arico M, Biondi A, Niemeyer CM (1999) RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 13:32&#x2013;37 <pub-id pub-id-type="pmid">10049057</pub-id></citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalra</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Paderanga</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Olson</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
          <article-title>Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras</article-title>
          <source>Blood</source>
          <year>1994</year>
          <volume>84</volume>
          <fpage>3435</fpage>
          <lpage>3439</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kalra R, Paderanga DC, Olson K, Shannon KM (1994) Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood 84:3435&#x2013;3439 <pub-id pub-id-type="pmid">7949098</pub-id></citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lauchle</surname>
              <given-names>JO</given-names>
            </name>
            <name>
              <surname>Braun</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Loh</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Inherited predispositions and hyperactive Ras in myeloid leukemogenesis</article-title>
          <source>Pediatr Blood Cancer</source>
          <year>2006</year>
          <volume>46</volume>
          <fpage>579</fpage>
          <lpage>585</lpage>
          <pub-id pub-id-type="doi">10.1002/pbc.20644</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lauchle JO, Braun BS, Loh ML, Shannon K (2006) Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatr Blood Cancer 46:579&#x2013;585 <pub-id pub-id-type="pmid">16261595</pub-id></citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braun</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Tuveson</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Le</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Kogan</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Rozmus</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Le Beau</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Jacks</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
          <article-title>Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2004</year>
          <volume>101</volume>
          <fpage>597</fpage>
          <lpage>602</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0307203101</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM (2004) Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A 101:597&#x2013;602 <pub-id pub-id-type="pmid">14699048</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chan</surname>
              <given-names>IT</given-names>
            </name>
            <name>
              <surname>Kutok</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Shigematsu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Akashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tuveson</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Jacks</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gilliland</surname>
              <given-names>DG</given-names>
            </name>
          </person-group>
          <article-title>Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease</article-title>
          <source>J Clin Invest</source>
          <year>2004</year>
          <volume>113</volume>
          <fpage>528</fpage>
          <lpage>538</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI200420476</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, Johnson L, Akashi K, Tuveson DA, Jacks T, Gilliland DG (2004) Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 113:528&#x2013;538 <pub-id pub-id-type="pmid">14966562</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bader-Meunier</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tchernia</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mielot</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Fontaine</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lyonnet</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lavergne</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Dommergues</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Occurrence of myeloproliferative disorder in patients with Noonan syndrome</article-title>
          <source>J Pediatr</source>
          <year>1997</year>
          <volume>130</volume>
          <fpage>885</fpage>
          <lpage>889</lpage>
          <pub-id pub-id-type="doi">10.1016/S0022-3476(97)70273-7</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bader-Meunier B, Tchernia G, Mielot F, Fontaine JL, Thomas C, Lyonnet S, Lavergne JM, Dommergues JP (1997) Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr 130:885&#x2013;889 <pub-id pub-id-type="pmid">9202609</pub-id></citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tartaglia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Niemeyer</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Fragale</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Buechner</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hahlen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hasle</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Licht</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Gelb</surname>
              <given-names>BD</given-names>
            </name>
          </person-group>
          <article-title>Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia</article-title>
          <source>Nat Genet</source>
          <year>2003</year>
          <volume>34</volume>
          <fpage>148</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="doi">10.1038/ng1156</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, Hahlen K, Hasle H, Licht JD, Gelb BD (2003) Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34:148&#x2013;150 <pub-id pub-id-type="pmid">12717436</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loh</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Vattikuti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schubbert</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Reynolds</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Carlson</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lieuw</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Stokoe</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bonifas</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Curtiss</surname>
              <given-names>NP</given-names>
            </name>
            <name>
              <surname>Gotlib</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Meshinchi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Beau</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Emanuel</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
          <article-title>Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis</article-title>
          <source>Blood</source>
          <year>2004</year>
          <volume>103</volume>
          <fpage>2325</fpage>
          <lpage>2331</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2003-09-3287</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, Cheng JW, Lee CM, Stokoe D, Bonifas JM, Curtiss NP, Gotlib J, Meshinchi S, Le Beau MM, Emanuel PD, Shannon KM (2004) Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103:2325&#x2013;2331 <pub-id pub-id-type="pmid">14644997</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kratz</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Niemeyer</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Castleberry</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Cetin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bergstrasser</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Emanuel</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Hasle</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kardos</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kojima</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Stary</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Trebo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zecca</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gelb</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Tartaglia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Loh</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
          <article-title>The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>106</volume>
          <fpage>2183</fpage>
          <lpage>2185</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2005-02-0531</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergstrasser E, Emanuel PD, Hasle H, Kardos G, Klein C, Kojima S, Stary J, Trebo M, Zecca M, Gelb BD, Tartaglia M, Loh ML (2005) The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 106:2183&#x2013;2185 <pub-id pub-id-type="pmid">15928039</pub-id></citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tartaglia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Martinelli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cazzaniga</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cordeddu</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Iavarone</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Spinelli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Palmi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Carta</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pession</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arico</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Masera</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Basso</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sorcini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gelb</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Biondi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia</article-title>
          <source>Blood</source>
          <year>2004</year>
          <volume>104</volume>
          <fpage>307</fpage>
          <lpage>313</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2003-11-3876</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tartaglia M, Martinelli S, Cazzaniga G, Cordeddu V, Iavarone I, Spinelli M, Palmi C, Carta C, Pession A, Arico M, Masera G, Basso G, Sorcini M, Gelb BD, Biondi A (2004) Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 104:307&#x2013;313 <pub-id pub-id-type="pmid">14982869</pub-id></citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bentires-Alj</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Paez</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Keilhack</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Halmos</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Naoki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maris</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Richardson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bardelli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sugarbaker</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Richards</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Girard</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Minna</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Loh</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Velculescu</surname>
              <given-names>VE</given-names>
            </name>
            <name>
              <surname>Vogelstein</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Meyerson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sellers</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Neel</surname>
              <given-names>BG</given-names>
            </name>
          </person-group>
          <article-title>Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia</article-title>
          <source>Cancer Res</source>
          <year>2004</year>
          <volume>64</volume>
          <fpage>8816</fpage>
          <lpage>8820</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1923</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, Richards WG, Du J, Girard L, Minna JD, Loh ML, Fisher DE, Velculescu VE, Vogelstein B, Meyerson M, Sellers WR, Neel BG (2004) Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64:8816&#x2013;8820 <pub-id pub-id-type="pmid">15604238</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schubbert</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lieuw</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Loh</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Clapp</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
          <article-title>Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>106</volume>
          <fpage>311</fpage>
          <lpage>317</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2004-11-4207</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Schubbert S, Lieuw K, Rowe SL, Lee CM, Li X, Loh ML, Clapp DW, Shannon KM (2005) Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 106:311&#x2013;317 <pub-id pub-id-type="pmid">15761018</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mohi</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>Dearolf</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kutok</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Boulton</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Shigematsu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Keilhack</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Akashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gilliland</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Neel</surname>
              <given-names>BG</given-names>
            </name>
          </person-group>
          <article-title>Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations</article-title>
          <source>Cancer Cell</source>
          <year>2005</year>
          <volume>7</volume>
          <fpage>179</fpage>
          <lpage>191</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ccr.2005.01.010</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Mohi MG, Williams IR, Dearolf CR, Chan G, Kutok JL, Cohen S, Morgan K, Boulton C, Shigematsu H, Keilhack H, Akashi K, Gilliland DG, Neel BG (2005) Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 7:179&#x2013;191 <pub-id pub-id-type="pmid">15710330</pub-id></citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chan</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Leedy</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Munugalavadla</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Voorhorst</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kapur</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>105</volume>
          <issue>9</issue>
          <fpage>3737</fpage>
          <lpage>3742</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2004-10-4002</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Chan RJ, Leedy MB, Munugalavadla V, Voorhorst CS, Li Y, Yu M, Kapur R (2005) Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Blood 105(9):3737-3742 <pub-id pub-id-type="pmid">15644411</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keilhack</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>McGregor</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cantley</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Neel</surname>
              <given-names>BG</given-names>
            </name>
          </person-group>
          <article-title>Diverse biochemical properties of Shp2 mutants: implications for disease phenotypes</article-title>
          <source>J Biol Chem</source>
          <year>2005</year>
          <volume>280</volume>
          <fpage>30984</fpage>
          <lpage>30993</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M504699200</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Keilhack H, David FS, McGregor M, Cantley LC, Neel BG (2005) Diverse biochemical properties of Shp2 mutants: implications for disease phenotypes. J Biol Chem 280:30984&#x2013;30993 <pub-id pub-id-type="pmid">15987685</pub-id></citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Araki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mohi</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Ismat</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Bronson</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>Kutok</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Pao</surname>
              <given-names>LI</given-names>
            </name>
            <name>
              <surname>Gilliland</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Epstein</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Neel</surname>
              <given-names>BG</given-names>
            </name>
          </person-group>
          <article-title>Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation</article-title>
          <source>Nat Med</source>
          <year>2004</year>
          <volume>10</volume>
          <fpage>849</fpage>
          <lpage>857</lpage>
          <pub-id pub-id-type="doi">10.1038/nm1084</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL, Yang W, Pao LI, Gilliland DG, Epstein JA, Neel BG (2004) Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 10:849&#x2013;857 <pub-id pub-id-type="pmid">15273746</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Side</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Emanuel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Franklin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Castleberry</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Mutations of the NF1 gene in leukemias from children without evidence of neurofibromatosis, type 1</article-title>
          <source>Blood</source>
          <year>1998</year>
          <volume>92</volume>
          <fpage>267</fpage>
          <lpage>273</lpage>
        </citation>
        <citation citation-type="display-unstructured">Side L, Emanuel P, Taylor B, Franklin J, Thompson P, Castleberry R, Shannon K (1998) Mutations of the NF1 gene in leukemias from children without evidence of neurofibromatosis, type 1. Blood 92:267&#x2013;273 <pub-id pub-id-type="pmid">9639526</pub-id></citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shannon</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>O&#x2019;Connell</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Paderanga</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Olson</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dinndorf</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>McCormick</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders</article-title>
          <source>N Engl J Med</source>
          <year>1994</year>
          <volume>330</volume>
          <fpage>597</fpage>
          <lpage>601</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199403033300903</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Shannon KM, O&#x2019;Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P, McCormick F (1994) Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 330:597&#x2013;601 <pub-id pub-id-type="pmid">8302341</pub-id></citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation citation-type="other">Stephens K, Weaver M, Leppig KA, Maruyama K, Emanuel PD, Le Beau MM, Shannon KM (2006) Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood</citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bollag</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Clapp</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Shih</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Adler</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>YY</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lange</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Freedman</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>McCormick</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Jacks</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells</article-title>
          <source>Nat Genet</source>
          <year>1996</year>
          <volume>12</volume>
          <fpage>144</fpage>
          <lpage>148</lpage>
          <pub-id pub-id-type="doi">10.1038/ng0296-144</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K (1996) Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12:144&#x2013;148 <pub-id pub-id-type="pmid">8563751</pub-id></citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Largaespada</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Brannan</surname>
              <given-names>CI</given-names>
            </name>
            <name>
              <surname>Jenkins</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Copeland</surname>
              <given-names>NG</given-names>
            </name>
          </person-group>
          <article-title>Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia</article-title>
          <source>Nat Genet</source>
          <year>1916</year>
          <volume>12</volume>
          <fpage>137</fpage>
          <lpage>143</lpage>
          <pub-id pub-id-type="doi">10.1038/ng0296-137</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Largaespada DA, Brannan CI, Jenkins NA, Copeland NG (1996) Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 12:137&#x2013;143 <pub-id pub-id-type="pmid">8563750</pub-id></citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Le</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Lauchle</surname>
              <given-names>JO</given-names>
            </name>
            <name>
              <surname>Aiyigari</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Braun</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kogan</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Le Beau</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Parada</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
          <article-title>Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder</article-title>
          <source>Blood</source>
          <year>2004</year>
          <volume>103</volume>
          <fpage>4243</fpage>
          <lpage>4250</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2003-08-2650</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, Wang E, Kogan SC, Le Beau MM, Parada L, Shannon KM (2004) Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 103:4243&#x2013;4250 <pub-id pub-id-type="pmid">14982883</pub-id></citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colley</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Donnai</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>DG</given-names>
            </name>
          </person-group>
          <article-title>Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis</article-title>
          <source>Clin Genet</source>
          <year>1996</year>
          <volume>49</volume>
          <fpage>59</fpage>
          <lpage>64</lpage>
        </citation>
        <citation citation-type="display-unstructured">Colley A, Donnai D, Evans DG (1996) Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis. Clin Genet 49:59&#x2013;64 <pub-id pub-id-type="pmid">8740913</pub-id></citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luca</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bottillo</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Sarkozy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carta</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Neri</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bellacchio</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schirinzi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Conti</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Zampino</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Battaglia</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Majore</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rinaldi</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Carella</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Marino</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Pizzuti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Digilio</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Tartaglia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dallapiccola</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome</article-title>
          <source>Am J Hum Genet</source>
          <year>2005</year>
          <volume>77</volume>
          <fpage>1092</fpage>
          <lpage>1101</lpage>
          <pub-id pub-id-type="doi">10.1086/498454</pub-id>
        </citation>
        <citation citation-type="display-unstructured">De Luca A, Bottillo I, Sarkozy A, Carta C, Neri C, Bellacchio E, Schirinzi A, Conti E, Zampino G, Battaglia A, Majore S, Rinaldi MM, Carella M, Marino B, Pizzuti A, Digilio MC, Tartaglia M, Dallapiccola B (2005) NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. Am J Hum Genet 77:1092&#x2013;1101 <pub-id pub-id-type="pmid">16380919</pub-id></citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zenker</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Buheitel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rauch</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Koenig</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bosse</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kress</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Tietze</surname>
              <given-names>HU</given-names>
            </name>
            <name>
              <surname>Doerr</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Hofbeck</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Singer</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Reis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rauch</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Genotype&#x2013;phenotype correlations in Noonan syndrome</article-title>
          <source>J Pediatr</source>
          <year>2004</year>
          <volume>144</volume>
          <fpage>368</fpage>
          <lpage>374</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jpeds.2003.11.032</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Zenker M, Buheitel G, Rauch R, Koenig R, Bosse K, Kress W, Tietze HU, Doerr HG, Hofbeck M, Singer H, Reis A, Rauch A (2004) Genotype&#x2013;phenotype correlations in Noonan syndrome. J Pediatr 144:368&#x2013;374 <pub-id pub-id-type="pmid">15001945</pub-id></citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schubbert</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zenker</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Boll</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bollag</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Burgt</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Musante</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kalscheuer</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Wehner</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>West</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>KY</given-names>
            </name>
            <name>
              <surname>Sistermans</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rauch</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Niemeyer</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kratz</surname>
              <given-names>CP</given-names>
            </name>
          </person-group>
          <article-title>Germline KRAS mutations cause Noonan syndrome</article-title>
          <source>Nat Genet</source>
          <year>2006</year>
          <volume>38</volume>
          <fpage>331</fpage>
          <lpage>336</lpage>
          <pub-id pub-id-type="doi">10.1038/ng1748</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP (2006) Germline KRAS mutations cause Noonan syndrome. Nat Genet 38:331&#x2013;336 <pub-id pub-id-type="pmid">16474405</pub-id></citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aoki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Niihori</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kawame</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kurosawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ohashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Filocamo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kure</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Germline mutations in HRAS proto-oncogene cause Costello syndrome</article-title>
          <source>Nat Genet</source>
          <year>2005</year>
          <volume>37</volume>
          <fpage>1038</fpage>
          <lpage>1040</lpage>
          <pub-id pub-id-type="doi">10.1038/ng1641</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, Filocamo M, Kato K, Suzuki Y, Kure S, Matsubara Y (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37:1038&#x2013;1040 <pub-id pub-id-type="pmid">16170316</pub-id></citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niihori</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Aoki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Narumi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Neri</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cave</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Verloes</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Okamoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hennekam</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Gillessen-Kaesbach</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wieczorek</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kavamura</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Kurosawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ohashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Heron</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bonneau</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Corona</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kaname</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Naritomi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Baumann</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kure</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Germline KRAS and BRAF mutations in cardio&#x2013;facio&#x2013;cutaneous syndrome</article-title>
          <source>Nat Genet</source>
          <year>2006</year>
          <volume>38</volume>
          <fpage>294</fpage>
          <lpage>296</lpage>
          <pub-id pub-id-type="doi">10.1038/ng1749</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Okamoto N, Hennekam RC, Gillessen-Kaesbach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y (2006) Germline KRAS and BRAF mutations in cardio&#x2013;facio&#x2013;cutaneous syndrome. Nat Genet 38:294&#x2013;296 <pub-id pub-id-type="pmid">16474404</pub-id></citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rodriguez-Viciana</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Tetsu</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Tidyman</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Estep</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Conger</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Cruz</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>McCormick</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rauen</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
          <article-title>Germline mutations in genes within the MAPK pathway cause cardio&#x2013;facio&#x2013;cutaneous syndrome</article-title>
          <source>Science</source>
          <year>2006</year>
          <volume>311</volume>
          <fpage>1287</fpage>
          <lpage>1290</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1124642</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA (2006) Germline mutations in genes within the MAPK pathway cause cardio&#x2013;facio&#x2013;cutaneous syndrome. Science 311:1287&#x2013;1290 <pub-id pub-id-type="pmid">16439621</pub-id></citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carta</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pantaleoni</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bocchinfuso</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Stella</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Vasta</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Sarkozy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Digilio</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Palleschi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pizzuti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Grammatico</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Zampino</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Dallapiccola</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gelb</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Tartaglia</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype</article-title>
          <source>Am J Hum Genet</source>
          <year>2006</year>
          <volume>79</volume>
          <fpage>129</fpage>
          <lpage>135</lpage>
          <pub-id pub-id-type="doi">10.1086/504394</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, Sarkozy A, Digilio C, Palleschi A, Pizzuti A, Grammatico P, Zampino G, Dallapiccola B, Gelb BD, Tartaglia M (2006) Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet 79:129&#x2013;135 <pub-id pub-id-type="pmid">16773572</pub-id></citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Margarit</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Sondermann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Nagar</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hoelz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pirruccello</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bar-Sagi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kuriyan</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Structural evidence for feedback activation by Ras. GTP of the Ras-specific nucleotide exchange factor SOS</article-title>
          <source>Cell</source>
          <year>2003</year>
          <volume>112</volume>
          <fpage>685</fpage>
          <lpage>695</lpage>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(03)00149-1</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Margarit SM, Sondermann H, Hall BE, Nagar B, Hoelz A, Pirruccello M, Bar-Sagi D, Kuriyan J (2003) Structural evidence for feedback activation by Ras. GTP of the Ras-specific nucleotide exchange factor SOS. Cell 112:685&#x2013;695 <pub-id pub-id-type="pmid">12628188</pub-id></citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation citation-type="other">Zenker M, Lehmann K, Schulz AL, Barth CF, Hansmann D, Koenig R, Korinthenberg R, Kreiss-Nachtsheim M, Meinecke P, Morlot S, Mundlos S, Quante AS, Raskin S, Schnabel D, Wehner LE, Kratz CP, Horn D, Kutsche K (2006) Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 2006 Oct 20; [Epub ahead of print]</citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stone</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Colleton</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bottorff</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Effector domain mutations dissociate p21ras effector function and GTPase-activating protein interaction</article-title>
          <source>Mol Cell Biol</source>
          <year>1993</year>
          <volume>13</volume>
          <fpage>7311</fpage>
          <lpage>7320</lpage>
        </citation>
        <citation citation-type="display-unstructured">Stone JC, Colleton M, Bottorff D (1993) Effector domain mutations dissociate p21ras effector function and GTPase-activating protein interaction. Mol Cell Biol 13:7311&#x2013;7320 <pub-id pub-id-type="pmid">8246952</pub-id></citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bignell</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stephens</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Edkins</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Clegg</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Teague</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Woffendin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Garnett</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Bottomley</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Dicks</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ewing</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Floyd</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hawes</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kosmidou</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Menzies</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mould</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Watt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hooper</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jayatilake</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gusterson</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Shipley</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hargrave</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pritchard-Jones</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maitland</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Chenevix-Trench</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Riggins</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Bigner</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Palmieri</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cossu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Flanagan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nicholson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Yuen</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Seigler</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Darrow</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Paterson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Marais</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Wooster</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Stratton</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Futreal</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Mutations of the BRAF gene in human cancer</article-title>
          <source>Nature</source>
          <year>2002</year>
          <volume>417</volume>
          <fpage>949</fpage>
          <lpage>954</lpage>
          <pub-id pub-id-type="doi">10.1038/nature00766</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949&#x2013;954 <pub-id pub-id-type="pmid">12068308</pub-id></citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gripp</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Stabley</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Nicholson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>CI</given-names>
            </name>
            <name>
              <surname>Doyle</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Aoki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zackai</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Lapunzina</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gonzalez-Meneses</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Holbrook</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Agresta</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>IL</given-names>
            </name>
            <name>
              <surname>Sol-Church</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation</article-title>
          <source>Am J Med Genet A</source>
          <year>2006</year>
          <volume>140</volume>
          <fpage>1</fpage>
          <lpage>7</lpage>
        </citation>
        <citation citation-type="display-unstructured">Gripp KW, Lin AE, Stabley DL, Nicholson L, Scott CI, Jr., Doyle D, Aoki Y, Matsubara Y, Zackai EH, Lapunzina P, Gonzalez-Meneses A, Holbrook J, Agresta CA, Gonzalez IL, Sol-Church K (2006) HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A 140:1&#x2013;7 <pub-id pub-id-type="pmid">16329078</pub-id></citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kerr</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Delrue</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Sigaudy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Perveen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Marche</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Burgelin</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Stef</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Eden</surname>
              <given-names>OB</given-names>
            </name>
            <name>
              <surname>O&#x2019;Sullivan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sandre-Giovannoli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Reardon</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Brewer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Quarell</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>M&#x2019;Cann</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Donnai</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hennekam</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cave</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Verloes</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Philip</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lacombe</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Arveiler</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Genotype&#x2013;phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases</article-title>
          <source>J Med Genet</source>
          <year>2006</year>
          <volume>43</volume>
          <fpage>401</fpage>
          <lpage>405</lpage>
          <pub-id pub-id-type="doi">10.1136/jmg.2005.040352</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kerr B, Delrue MA, Sigaudy S, Perveen R, Marche M, Burgelin I, Stef M, Tang B, Eden OB, O&#x2019;Sullivan J, De Sandre-Giovannoli A, Reardon W, Brewer C, Bennett C, Quarell O, M&#x2019;Cann E, Donnai D, Stewart F, Hennekam R, Cave H, Verloes A, Philip N, Lacombe D, Levy N, Arveiler B, Black G (2006) Genotype&#x2013;phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet 43:401&#x2013;405 <pub-id pub-id-type="pmid">16443854</pub-id></citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Estep</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Tidyman</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Teitell</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Cotter</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Rauen</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
          <article-title>HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy</article-title>
          <source>Am J Med Genet A</source>
          <year>2006</year>
          <volume>140</volume>
          <fpage>8</fpage>
          <lpage>16</lpage>
        </citation>
        <citation citation-type="display-unstructured">Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA (2006) HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A 140:8&#x2013;16 <pub-id pub-id-type="pmid">16372351</pub-id></citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Greenbaum</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cichowski</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mercer</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schmitt</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bronson</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Umanoff</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Edelmann</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Kucherlapati</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jacks</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>K-ras is an essential gene in the mouse with partial functional overlap with N-ras</article-title>
          <source>Genes Dev</source>
          <year>1997</year>
          <volume>11</volume>
          <fpage>2468</fpage>
          <lpage>2481</lpage>
        </citation>
        <citation citation-type="display-unstructured">Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, Schmitt E, Bronson RT, Umanoff H, Edelmann W, Kucherlapati R, Jacks T (1997) K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev 11:2468&#x2013;2481 <pub-id pub-id-type="pmid">9334313</pub-id></citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mor</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Philips</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Compartmentalized Ras/MAPK signaling</article-title>
          <source>Annu Rev Immunol</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>771</fpage>
          <lpage>800</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.immunol.24.021605.090723</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Mor A, Philips MR (2006) Compartmentalized Ras/MAPK signaling. Annu Rev Immunol 24:771&#x2013;800 <pub-id pub-id-type="pmid">16551266</pub-id></citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rocks</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Peyker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kahms</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Verveer</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Koerner</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lumbierres</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kuhlmann</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Waldmann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wittinghofer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bastiaens</surname>
              <given-names>PI</given-names>
            </name>
          </person-group>
          <article-title>An acylation cycle regulates localization and activity of palmitoylated Ras isoforms</article-title>
          <source>Science</source>
          <year>2005</year>
          <volume>307</volume>
          <fpage>1746</fpage>
          <lpage>1752</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1105654</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rocks O, Peyker A, Kahms M, Verveer PJ, Koerner C, Lumbierres M, Kuhlmann J, Waldmann H, Wittinghofer A, Bastiaens PI (2005) An acylation cycle regulates localization and activity of palmitoylated Ras isoforms. Science 307:1746&#x2013;1752 <pub-id pub-id-type="pmid">15705808</pub-id></citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rauen</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
          <article-title>Distinguishing Costello versus cardio&#x2013;facio&#x2013;cutaneous syndrome: BRAF mutations in patients with a Costello phenotype</article-title>
          <source>Am J Med Genet</source>
          <year>2006</year>
          <volume>140</volume>
          <fpage>1681</fpage>
          <lpage>1683</lpage>
          <pub-id pub-id-type="doi">10.1002/ajmg.a.31315</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rauen KA (2006) Distinguishing Costello versus cardio&#x2013;facio&#x2013;cutaneous syndrome: BRAF mutations in patients with a Costello phenotype. Am J Med Genet 140:1681&#x2013;1683 </citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bentires-Alj</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kontaridis</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Neel</surname>
              <given-names>BG</given-names>
            </name>
          </person-group>
          <article-title>Stops along the RAS pathway in human genetic disease</article-title>
          <source>Nat Med</source>
          <year>2006</year>
          <volume>12</volume>
          <fpage>283</fpage>
          <lpage>285</lpage>
          <pub-id pub-id-type="doi">10.1038/nm0306-283</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bentires-Alj M, Kontaridis MI, Neel BG (2006) Stops along the RAS pathway in human genetic disease. Nat Med 12:283&#x2013;285 <pub-id pub-id-type="pmid">16520774</pub-id></citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>H&#xFC;ffmeier</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Zenker</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hoyer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fahsold</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rauch</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>A variable combination of features of Noonan syndrome and neurofibromatosis type I are caused by mutations in the NF1 gene</article-title>
          <source>Am J Med Genet A</source>
          <year>2006</year>
          <volume>140</volume>
          <fpage>2749</fpage>
          <lpage>2756</lpage>
        </citation>
        <citation citation-type="display-unstructured">H&#xFC;ffmeier U, Zenker M, Hoyer J, Fahsold R, Rauch A (2006) A variable combination of features of Noonan syndrome and neurofibromatosis type I are caused by mutations in the NF1 gene. Am J Med Genet A 140:2749&#x2013;2756 <pub-id pub-id-type="pmid">17103458</pub-id></citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bertola</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Passetti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>de Oliveira</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Messiaen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gelb</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Krieger</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>Neurofibromatosis&#x2013;Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient</article-title>
          <source>Am J Med Genet A</source>
          <year>2005</year>
          <volume>136</volume>
          <fpage>242</fpage>
          <lpage>245</lpage>
        </citation>
        <citation citation-type="display-unstructured">Bertola DR, Pereira AC, Passetti F, de Oliveira PS, Messiaen L, Gelb BD, Kim CA, Krieger JE (2005) Neurofibromatosis&#x2013;Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient. Am J Med Genet A 136:242&#x2013;245 <pub-id pub-id-type="pmid">15948193</pub-id></citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kratz</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Schubbert</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bollag</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Niemeyer</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Zenker</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders</article-title>
          <source>Cell Cycle</source>
          <year>2006</year>
          <volume>5</volume>
          <fpage>1607</fpage>
          <lpage>1611</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kratz CP, Schubbert S, Bollag G, Niemeyer CM, Shannon KM, Zenker M (2006) Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders. Cell Cycle 5:1607&#x2013;1611 <pub-id pub-id-type="pmid">16921267</pub-id></citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>CFC syndrome</term>
          <def>
            <p>cardio&#x2013;facio&#x2013;cutaneous syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>CS</term>
          <def>
            <p>Costello syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>GAP</term>
          <def>
            <p>GTPase activating protein</p>
          </def>
        </def-item>
        <def-item>
          <term>GDP</term>
          <def>
            <p>guanosine diphosphate</p>
          </def>
        </def-item>
        <def-item>
          <term>GEF</term>
          <def>
            <p>guanosine nucleotide exchange factor</p>
          </def>
        </def-item>
        <def-item>
          <term>GTP</term>
          <def>
            <p>guanosine triphosphate</p>
          </def>
        </def-item>
        <def-item>
          <term>JMML</term>
          <def>
            <p>juvenile myelomonocytic leukemia</p>
          </def>
        </def-item>
        <def-item>
          <term>LS</term>
          <def>
            <p>LEOPARD syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>MPD</term>
          <def>
            <p>myeloproliferative disorder</p>
          </def>
        </def-item>
        <def-item>
          <term>NCFC syndrome</term>
          <def>
            <p>neuro&#x2013;cardio&#x2013;facial&#x2013;cutaneous syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>NF1</term>
          <def>
            <p>neurofibromatosis type 1</p>
          </def>
        </def-item>
        <def-item>
          <term>NFNS</term>
          <def>
            <p>neurofibromatosis&#x2013;Noonan syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>NS</term>
          <def>
            <p>Noonan syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>N-SH2</term>
          <def>
            <p>n-terminal src-homology 2 domain</p>
          </def>
        </def-item>
        <def-item>
          <term>NS/JMML</term>
          <def>
            <p>Noonan syndrome in association with JMML</p>
          </def>
        </def-item>
        <def-item>
          <term>PTPase</term>
          <def>
            <p>phosphatase domain</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
  </back>
</article>
</pmc-articleset>